GH Stack dosage

CJC-1295 (no DAC) · Injectable

Reported-use amounts for CJC-1295 (no DAC) are 100–200 mcg per administration, 1–3x daily, for 8–12 wk. A gradual subcutaneous progression starts at 100 mcg in weeks 1–2, increases to 150 mcg in weeks 3–4, then reaches 200–300 mcg in weeks 5–12. Schedules include once-daily administration and a separate two-to-three-times-weekly pattern.[20][21]

The no-DAC form is a short-acting Modified GRF 1-29 analogue. Its pulse-oriented GH signaling differs from the prolonged action of DAC-containing CJC-1295.[10][11][2][12][13][20]

Ipamorelin · Injectable

Reported injectable protocols use 200–300 mcg per administration, 1-3 times daily for 8-12 weeks. A gradual bedtime progression starts at 100 mcg per subcutaneous injection in weeks 1–2, increases to 150 mcg in weeks 3–4, then reaches 200 mcg in weeks 5–8 and 250 mcg in weeks 9–12. One cycle pattern runs for 8–12 weeks followed by a 2–4-week break.[6][16][17][18][22]

Ipamorelin activates the ghrelin receptor and triggers growth-hormone release. GH-pulse activity does not itself establish improved recovery, sleep or body composition.[6][16][5]

Ipamorelin · Intranasal

Reported intranasal protocols use 200 mcg per administration, daily for 4 weeks.[6][16][17][18]

Ipamorelin activates the ghrelin receptor and triggers growth-hormone release. GH-pulse activity does not itself establish improved recovery, sleep or body composition.[17][18][5][6][16]

Frequency and timing

CJC-1295 (no DAC): Common injection timing is morning, after a workout or before bed.[11][20]

Ipamorelin: Common timing is before bed or after a workout, usually away from food.[6][16][17][18]

Cycle length and breaks

CJC-1295 (no DAC): Injectable: 8–12 wk. A standard break interval between courses is not established.[20]

Ipamorelin: Injectable: 8-12 weeks. Intranasal: 4 weeks. One reported subcutaneous cycle pattern includes a 2–4-week break after 8–12 weeks of use.[6][16][17][18][22]

Combination and product quality

This stack uses the short-acting no-DAC form, with different exposure from CJC-1295 DAC. Product identity and microgram dose precision matter. IGF-1, glucose, fluid retention, numbness or tingling, sleep symptoms and blood pressure require attention; anti-doping restrictions are also relevant.[2][3][4][9][8]

Side effects and long-term safety

CJC-1295 (no DAC): Injection-site reactions, flushing, headache, dizziness, blood-pressure symptoms and faster heart rate are relevant adverse effects. Long-term endocrine safety, glucose effects, interactions and product purity remain uncertain.[1][14][13][8]

Ipamorelin: Water retention, appetite change, glucose and IGF-1 effects, and local injection tolerance are relevant concerns. Injectable product quality, pregnancy, active malignancy and sports restrictions also require attention.[5][7]

Route-specific dosing limits

Separate products and fixed-ratio blends have different preparation requirements. Keep the exact formulation, component amount and route with each recorded dose. Reported-use schedules for CJC-1295 (no DAC) (injectable) are not established human treatment regimens.[20][21]